AIM Specialty Health Partners with eviti to Help Power Next Generation Oncology Solutions

  AIM Specialty Health Partners with eviti to Help Power Next Generation
  Oncology Solutions

Business Wire

CHICAGO -- March 7, 2013

AIM Specialty Health, a national leader in specialty benefits management, has
announced a strategic collaboration with eviti, Inc. to create an enhanced
oncology management solution that helps ensure appropriate, safe and
affordable cancer care. eviti is the leader in oncology clinical
decision-support focused on improving the quality and reducing the costs of
care.

AIM’s new Integrated Oncology Solution will build on its heritage of promoting
the most appropriate and cost effective use of clinical services including
radiology, cardiology, oncology, specialty drugs and sleep medicine. In
collaboration with eviti, AIM will deliver a comprehensive solution that
targets the use of evidence-based treatment pathways across all tumor types.
Through AIM’s proven business platform, physicians will be empowered with
real-time, advanced cancer care decision support information and reimbursement
verification. Health plan members will benefit from clinically effective,
evidence-based treatment options recommended by their physicians. AIM’s
current oncology solution covers 11 million members and will migrate to the
enhanced, integrated solution on AIM’s expanding platform.

“Cancer care represents a significant and growing portion of healthcare
spending with about a third of all treatment plans failing to meet nationally
accepted standards. AIM’s solution will integrate comprehensive clinical
evidence with treatment alternatives and reimbursement to help ensure the most
effective treatment from the start – for patients, providers, health plans and
their employer customers,” said Brandon Cady, president and CEO of AIM
Specialty Health.

Cady added, “eviti represents a highly credible clinical decision support
reference for cancer care, which makes the company ideal to help us deliver an
integrated solution that goes beyond simply promoting clinical pathways to the
oncology community. Our solution will help physicians make sure patients are
receiving clinically effective treatments while the solution also aligns
financial incentives from the payer. The end result will be improved quality
and affordability for the entire system.”

“Treating cancer today is a complex business,” noted eviti, Inc. CEO Eduardo
Beruff. “Taking into consideration all the toxicities, costs and outcomes of
nationally accepted treatment options could be overwhelming and nearly
impossible without the right information at the time of decision-making for
the clinician and his/her patient. We are excited to be working with AIM to
integrate our oncology decision support expertise into their next generation
oncology solution. Together, we can achieve our mutual goals to eliminate
inappropriate treatment and empower the alignment of quality care with
appropriate reimbursement.”

About Oncology Clinical Decision Making

According to numerous articles published in the Journal of Clinical Oncology
and other peer-reviewed medical journals, 32 percent of treatment plans
deviate from evidence-based medicine. Studies also show oncology patient
treatment plan compliance at just 45 percent. As scientific breakthroughs and
personalized medicine advances, physicians are faced with an increasing number
of treatment decisions. The National Cancer Institute predicts that by the end
of this decade physicians may need to weigh 100 facts for each decision and,
by 2025, the number of facts per treatment decision will grow to 1,000.
Without support at the point of clinical decision making, new therapies and
their appropriate use may lag and put further strain on the healthcare system.

About AIM

AIM Specialty Health is a national leader in specialty benefits management
driving more appropriate, safe and affordable care throughout the healthcare
system. For more than 35 million members covered across 50 states, D.C. and US
territories, AIM targets the quality and cost of clinical services including
radiology, cardiology, oncology, specialty drugs and sleep medicine. Clients
including 43 health plans and over 100 national employers throughout the
country realize proven value with AIM’s integrated solution suite that
leverages clinical excellence, technology and superior customer service. AIM
is a wholly owned subsidiary of WellPoint, Inc. (WLP). For more information,
visit www.aimspecialtyhealth.com.

About eviti

eviti, Inc. is a leading health information technology and clinical
decision-support company delivering solutions to improve the quality of cancer
care and reduce its cost. eviti represents the culmination of almost a decade
of experience providing oncology treatment intelligence, uniquely delivering
value to all parties in the care process by ensuring quality care is
prescribed from the start. For more information, visitwww.eviti.com.

Contact:

AIM Specialty Health
Lori McLaughlin, 317.407.7403
lori.mclaughlin2@wellpoint.com
 
Press spacebar to pause and continue. Press esc to stop.